recall
saveBristol-Myers Squibb Company recall (Cls II)
community read0 votes
Opdualag (nivolumab and relatlimab-rmbw) injection, 240 mg and 80 mg/20 mL (12mg and 4mg/mL),Single Dose Vial, RX Only, Bristol-Myers Squibb Company, Princeton, NJ 08543, NDC 0003-7125-11 — Reason: Lack of Assurance of Sterility. — Status: Ongoing
view source ↗Data sources
last refreshed 2m ago
Found something off?
same company · ±60 days · 3
- approval(hyaluronidase (recombinant, human) + nivolumab): OPDIVO QVANTIG (NIVOLUMAB) — FDA approvalOct 27, 2025
- approval(hyaluronidase (recombinant, human) + nivolumab): OPDIVO QVANTIG (NIVOLUMAB) — FDA approvalOct 27, 2025
- approval(hyaluronidase (recombinant, human) + nivolumab): OPDIVO QVANTIG (NIVOLUMAB) — FDA approvalNov 24, 2025
🐶 often sniffed alongside
top 8- tagApproval166 co-mentions · 83 sources
- drugOPDIVO166 co-mentions · 83 sources
- drugOPDIVO QVANTIG166 co-mentions · 83 sources
- drugnivolumab166 co-mentions · 83 sources
- company$CELG-RIBRISTOL MYERS SQUIBB CO84 co-mentions · 84 sources
- tagDrug Shortage1 co-mentions · 1 sources
- drugazacitidine1 co-mentions · 1 sources
- drugOnureg1 co-mentions · 1 sources
comments(0)
5-min edit window · permanent after that